5月2日,开拓药业发布的临床观察试验结果显示,其自主研发的KX-826联合米诺地尔治疗中国成年男性雄激素性脱发(AGA)的疗效显著优于米诺地尔单药。图源:开拓药业官方公告此次试验共纳入75例患者,联合用药组(40例)采用0.5% KX-826酊联合5%米诺地尔酊每日两次外用,单药组(35例)仅使用5%米诺地尔酊。主要终点为目标区域非毳毛数量(TAHC)的变化。结果显示,联合用药组TAHC较基线增加...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.